Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PSTV files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsPlus Therapeutics reports Q1 2026 financial results and corporate updates
Filed May 15, 2026 · Period ending May 15, 2026 · ~1 min read
Key Changes
-
medium
Plus Therapeutics disclosed financial results for the quarter ended March 31, 2026, along with unspecified corporate updates via press release.
Item 2.02 verify on EDGAR → -
medium
The 8-K filing references a press release (Exhibit 99.1) containing the actual financial figures and operational details, which are not included in the filing body.
Item 9.01 verify on EDGAR →
Summary
Plus Therapeutics filed an 8-K to announce its first quarter 2026 financial results and recent corporate updates. The filing itself is procedural, serving as the formal SEC notification that the company issued a press release on May 15, 2026. The actual financial performance metrics, cash position, and operational updates are contained in the attached press release, which was not included in the analyzed filing text.
For retail investors, this is a standard quarterly earnings announcement. The materiality depends entirely on the contents of the press release—whether the company met expectations, how much cash remains on the balance sheet, and any pipeline or clinical trial updates mentioned in the corporate updates section.
Investors should review the full press release and any accompanying investor presentation to assess the company's financial health and progress on its therapeutic programs. Watch for management commentary on cash runway and upcoming clinical milestones in any earnings call or investor materials.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 15, 2026, Plus Therapeutics, Inc. (the “Company”) reported financial results for the first quarter ended March 31, 2026 and other recent corporate updates.
The company disclosed its financial results for the quarter ended March 31, 2026, along with unspecified corporate updates. The actual financial figures and details are contained in the press release (Exhibit 99.1), which is not included in this 8-K body text.
Event · Item 9.01 — Financial Statements and Exhibits
Item 9.01 — Financial Statements and Exhibits filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Press Release Announcing Financial Results, dated May 15, 2026
The company filed an 8-K to announce the issuance of a press release containing financial results. The actual financial details are contained in the attached press release (Exhibit 99.1), which is not included in this 8-K body text.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify